Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06917079 · ClinicalTrials.gov registry record · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 387
- Enrollment target
- 11
- Study locations
NCT06917079 is a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC that is actively recruiting participants, run by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics). The registered enrollment target is 387 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (41% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT06917079, a Phase 1 study of Non-Small Cell Lung Cancer and NSCLC, is actively recruiting participants, sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 387 participants
- Enrollment target
- 11
- Study locations
Study Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Pemetrexed
- DRUG Cetuximab
- DRUG BBO-11818
- DRUG Platinum chemotherapy (cisplatin or carboplatin)
Study Locations (11)
Texas
- Sarah Cannon Research Institute at Mary Crowley - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
California
- The Angeles Clinic and Research Institute - West Los Angeles Office - Los Angeles
- University of California San Diego Moores Cancer Center - San Diego
New York
- NYU Langone Health - New York
- Columbia University Irving Medical Center - New York
Florida
- Moffitt Cancer Center - Tampa
Massachusetts
- Massachusetts General Hospital - Boston
Utah
- Huntsman Cancer Institute - Salt Lake City
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2025-03-31 |
| Est. Completion | 2029-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06917079
The ClinicalTrials.gov registry entry for NCT06917079 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 387 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (41% lower). The listed sponsor is TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06917079 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT06917079 about?
NCT06917079 is a clinical study titled "BBO-11818 in Adult Subjects With KRAS Mutant Cancer". A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
What is the current status of trial NCT06917079?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 387 participants. The study started on 2025-03-31. Estimated completion is 2029-09.
What conditions does trial NCT06917079 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC, Colorectal Cancer, Metastatic Colorectal Cancer (CRC).
What interventions are being tested in trial NCT06917079?
The interventions under investigation include: Pembrolizumab (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG), BBO-11818 (DRUG), Platinum chemotherapy (cisplatin or carboplatin) (DRUG).
Who is sponsoring clinical trial NCT06917079?
This trial is sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics), which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06917079 being conducted?
This trial has 11 study locations across California, Florida, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.